Stelis Biopharma updates on receipt of consideration from Syngene

Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023

USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer

If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients

Lupin launches liquid fibre Softovac Liquifibre

Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients

Digital transformation key to managing rising organisational healthcare costs in India

Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024

AstraZeneca Pharma India to launch Enhertu in January 2024

Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer

Norms for fixing prices of medicines

NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201

NHA organizes a multi-stakeholder meet for ABDM microsites

ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring

Venus Remedies' R3SET forays into wellness

The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey

CII recognized Cadila among Top 50 Innovative Companies in India

Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease

Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation